Study of SHR-2173 for people with lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a body mass index (BMI) of 18 or higher.
- You must have been diagnosed with lupus for at least 6 months.
- You must have active lupus symptoms despite current treatment.
- You must be on at least one standard lupus medication (like steroids, antimalarials, or immunosuppressants).
- You must not have severe kidney problems, active infections, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection (CM313) to see if it can help people with active lupus. It's for those whose lupus symptoms aren't fully controlled despite standard treatments.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This trial tests an investigational drug called QLS4131 in people with active systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding QLS4131 can help control lupus activity better.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.